ClinicalTrials.gg
Not yet recruitingNCT07093268Updated Jul 30, 2025

Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis

A Phase 1 interventional study of Intrathecal Riluzole in Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by Brain Trust Bio. Not yet recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Brain Trust Bio · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.

Planned enrollment
38th of 44
10 · median 63
Started
2025
with 3 others
Phase 1
5 of 44
2 open now
Primary completion
2026-06
later than 2 of 12 live
Registered
37th of 44
by date

Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 38th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 2 of the 12 other live ones, and was the 37th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.

Read the detailed description

ALS/MND is a progressive motor neurone disease. Oral riluzole is approved for the treatment of ALS/MND in Australia as well as other countries. Unfortunately, in pill form, the drug's efficacy is limited by erratic absorption from the gut, dosing is limited by liver toxicity, and patients often experience brain fog as a troubling side effect. Evidence from dogs suggests that receiving the same drug through an implanted pump that infuses it directly into the cerebrospinal fluid around the cells that support breathing, allows these cells to get 3 to 10 times as much riluzole , and guarantees that it is always there at the desired amount. In addition, this delivery approach should not contribute to increased brain fog.

Patients who have demonstrated the ability to tolerate oral riluzole will have a SynchroMed® II Infusion Pump and Ascenda ® Intrathecal Catheter implanted. Once deemed medically appropriate, 6-weeks of continuous IT riluzole will be administered. Safety and tolerability will be assessed by a safety committee for the first 3 participants enrolled. With Safety Committee approval, these participants will continue on 6-months of treatment and a further 7 participants will be enrolled for a total of 32 weeks treatment.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease

Keywords

  • Neurodegenerative Diseases
  • Nervous System Diseases
  • Neuromuscular Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years or older.
  • Participants are ambulatory with or without an assistive device.
  • Sporadic or familial ALS diagnosis with possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
  • Slow vital capacity (SVC) measure ≥70% of predicted for gender, height, and age.
  • Medically able to undergo implantation of the SynchroMed II Infusion Pump according to the judgment of the investigator, or the presence of a previously implanted IT pump (not to be used for concurrent IT infusion of another IT agent).
  • Capable of reading and providing and following study procedures.
  • Geographic accessibility to the study center and the ability to travel to the clinic for study visits by ground transportation.
  • Women must not be able to become pregnant (eg, post menopausal, surgically sterile, or using adequate methods) for the duration of the study and 3 months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal (patch or contraceptive ring, for example) contraception), intrauterine device in place for ≥3 months, barrier method in conjunction with spermicide, or another adequate method.
  • Taking and tolerating oral riluzole 50 mg twice a day for at least 30 days prior screening and willingness to continue oral riluzole throughout duration of the study.
  • Patients may take other drugs approved for treatment of ALS at the dose prescribed by their neurologist.

Exclusion criteria

Exclusion Criteria:

  • Participants with bulbar-onset ALS
  • Participants at risk of increased bleeding or uncontrolled bleeding during the SynchroMed II Infusion Pump implantation or following explant. This includes but is not limited to:

    1. Anatomical factors at or near the site of implantation;
    2. Underlying disorders of the coagulation cascade or function (eg, hemophilia, Von Willebrand's disease, liver disease);
    3. Administration of antiplatelet or anticoagulant medication within 7 days before or after pump implantation (eg, aspirin, clopidogrel bisulfate, rivaroxaban, nonsteroidal anti-inflammatory agents [NSAIDs]), or
    4. Use of nutritional supplements (eg, St John's Wort) within 7 days before or after pump implantation.
  • Presence of infection including but not limited to: meningitis, ventriculitis, skin infection, bacteremia, or septicemia.
  • Testing positive for (anti-HIV antibody), (HBV surface antigen) or (anti-HCV antibody; HCV RNA if anti-HCV antibody is positive) at screening.
  • Inability to have the infusion pump implanted ≤ 2.5 cm below the skin surface.
  • Body weight and size unable to accept the infusion pump bulk and weight.
  • Spinal anomalies which would complicate the implantation and fixation of the catheter for IP delivery.
  • Serum (AST) and alanine aminotransferase (ALT) value > 2.0 times the upper normal.
  • A of less than 6 months, based on the judgment of the investigator.
  • Presence of tracheostomy.
  • The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair the ability of the participant to provide , per investigator judgment.
  • History of active substance abuse within the prior year.
  • At risk for committing suicide per investigator judgment.
  • history of unstable or severe cardiac, oncologic, hepatic, or renal disease, or other medically significant illness.
  • Pregnant women or women currently breastfeeding.
  • Exposure to any drug, device, or biologic within 30 days of screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Intrathecal riluzole continuous infusion up to 0.2 mg / hr.

    Drug: Intrathecal Riluzole

Interventions

  • Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal vital signs

    Serial assessment of adverse events, vital signs (blood pressure, pulse, respiratory rate and temp)

    Time frame: 6 weeks

  2. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with with abnormal physical examination findings

    Serial assessment of abnormal findings in a neurological examination for ALS patients

    Time frame: 6 weeks

  3. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal neurological exam findings

    Serial assessment all adverse events, neurological examination

    Time frame: 6 weeks

  4. Safety and tolerability of 0.2mg/hr intrathecal, infusion of intrathecal riluzole, Number of participants with with abnormal laboratory tests results

    Serial assessment all abnormal findings in clinical laboratory test results

    Time frame: 6 weeks

  5. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal findings in the Neuropathic Pain Scale (NPS)

    Serial assessment all abnormal findings in the Neuropathic Pain Scale (NPS)

    Time frame: 6 weeks

  6. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with adverse events, Columbia-Suicide Severity Rating Scale (C-SSRS).

    Serial assessment all adverse events in the Columbia-Suicide Severity Rating Scale (C-SSRS).

    Time frame: 6 weeks

Secondary outcomes

  1. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal vital signs

    Serial assessment of adverse events, vital signs (blood pressure, pulse, respiratory rate and temp)

    Time frame: 6 months

  2. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal physical examination findings

    Serial assessment of abnormal findings in a neurological examination for ALS patients

    Time frame: 6 months

  3. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal neurological exam findings

    Serial assessment all adverse events, neurological examination

    Time frame: 6 months

  4. Safety and tolerability of 0.2mg/hr intrathecal, infusion of intrathecal riluzole, Number of participants with with abnormal laboratory tests results

    Serial assessment all abnormal clinical laboratory test results

    Time frame: 6 months

  5. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with abnormal findings in the Neuropathic Pain Scale (NPS)

    Serial assessment all abnormal findings in the Neuropathic Pain Scale (NPS)

    Time frame: 6 months

  6. Safety and tolerability of 0.2mg/hr intrathecal infusion of intrathecal riluzole, Number of participants with adverse events, Columbia-Suicide Severity Rating Scale (C-SSRS).

    Serial assessment all adverse events in the Columbia-Suicide Severity Rating Scale (C-SSRS).

    Time frame: 6 months

Other outcomes

  1. Exploratory - Measure of changes in blood and cerebrospinal fluid biomarkers and urinary p75

    Measure of BDNF, pNFH and NfL) and cerebrospinal fluid (pNFH, NfL, Chit-1, CHI3L1, MCP-1, IL-6, IL-8, IL-17, IL-18, MIP-1α, TNF-α, CRP, 8-oxodG, Ferritin, BDNF, NGF, p75ECD biomarkers

    Time frame: 9 months

  2. Exploratory - Measure of clinical outcome of Handheld dynamometry (HHD) during dosing and post treatment periods.

    Measure of Handheld dynamometry (HHD)

    Time frame: 9 months

  3. Exploratory - Tracheostomy free survival

    To compare tracheostomy free survival for all participants with data from historical controls

    Time frame: 9 months

  4. Exploratory - Measure of clinical outcome measures during dosing and post treatment periods.

    Measure of the ALS Functional Rating Scale - Revised (ALSFRS-R),

    Time frame: 9 months

  5. Exploratory - Measure of clinical outcome measures during dosing and post treatment periods.

    Measure of slow vital capacity (SVC),

    Time frame: 9 months

  6. Exploratory - Measure of clinical outcome measures during dosing and post treatment periods.

    Measure of the Rasch-Built Overall ALS Disability Scale (ROADS),

    Time frame: 9 months

  7. Exploratory - Measure of clinical outcome measures during dosing and post treatment periods.

    Measure of the Amyotrophic Lateral Sclerosis-Specific Quality of Life-short form (ALSSQOL-SF)

    Time frame: 9 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Jun 2026, 10 months later.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 10 months is below that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2024
First posted
Jul 30, 2025
StartEst.
Aug 15, 2025
Primary completionEst.
Jun 15, 2026
CompletionEst.
Jan 15, 2027
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07093268
Lead sponsor
Brain Trust Bio
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Aug 15, 2025 (estimated)
Primary completion
Jun 15, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Jul 30, 2025

Study contacts

Chen Benkler, PhD
Contact
chen.benkler@gmail.com
+1 857 285 8300
Tina Soulis, PhD
Contact
tina.soulis@alithialifesciences.com
+61 429 300 705
David Schultz, Dr
principal investigator · Flinders Medical Centre
Antony Winkel, Dr
principal investigator · Sunshine Coast University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riluzole

Start the discussion